Glamand Fashion News

Head and Neck Cancer Clinical Trials

(Albany, USA) DelveInsight’s ‘Head and Neck Cancer Pipeline Insight 2024’ report provides comprehensive global coverage of available, marketed, and pipeline head and neck cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the head and neck cancer pipeline domain.

Request for a free sample report @ Head and Neck Cancer Pipeline Analysis

Key Takeaways from the Head and Neck Cancer Pipeline Report

• DelveInsight’s head and neck cancer pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for head and neck cancer treatment. 
• Key head and neck cancer companies such as Innate Pharma, GlaxoSmithKline, Debiopharm, Checkpoint Therapeutics, Quadriga BioSciences, Palleon Pharmaceuticals, Klus Pharma, Bicycle Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Memgen, I-Mab Biopharma, Intensity Therapeutics, Wellmaker Bio, SN BioScience, Carisma Therapeutics, Genentech, Pionyr Immunotherapeutics, Palleon Pharmaceuticals, SN BioScience, Bicycle Therapeutics, Inhibrx, Celldex Therapeutics, Carisma Therapeutics Inc, BioAtla, Jacobio Pharmaceuticals, Compugen, GeoVax, CytomX Therapeutics, PNP Therapeutics, Galectin Therapeutics, Cyteir Therapeutics, Merck KGaA, Boehringer Ingelheim, Transgene, iTeos Therapeutics SA,  IntraGel Therapeutics, Incyte Corporation, Cue Biopharma, Rubius Therapeutics, Alkermes, Corregene Biotechnology, NanoCarrier, Kura Oncology, Betta Pharmaceuticals, Arcus Biosciences, Taiho Pharmaceutical, Astex Pharmaceuticals, Bayer HealthCare, Roche, Vaccinex, Pfizer, BioNTech,  Purple Biotech, Novartis Oncology, Macrogenics, Aveta Biomics, Cellectar Biosciences, Nanobiotix, Nektar Therapeutics, Istari Oncology, Nanobiotix, Aspyrian Therapeutics, and others are evaluating new head and neck cancer drugs to improve the treatment landscape.
• Promising head and neck cancer pipeline therapies such as Niraparib, Xevinapant, , CK-301, QBS10072S, A166, E-602, BT5528, RAPA-201, Mitoxantrone Hydrochloride, MEM-288, TJ004309, SNB-101, INT230-6, CT-0508, WM-S1-030, CDX-1140, PY159, MCLA-129, INBRX-106, Autogene cevumeran, JAB-3068, CAB-ROR2-ADC, CX-2029, Ad/PNP, COM701, Eftilagimod alpha, CYT-0851, GR-MD-02, TG4050, BI 765063, TumoCure, EOS-448, Epacadostat, RTX-321, CUE-101, ALKS 4230, CRTE7A2-01, NC-6004, Tipifarnib, MCLA-129, Zimberelimab, HLX10 Plus HLX07, Tolinapant, BAY1905254, OSI-774, VX15/2503, Palbociclib, Olaparib, NT219, BNT113, Buparlisib, Retifanlimab, Avelumab, APG-157, CLR 131, NBTXR3, Evorpacept, Dostarlimab, NKTR-214, IK-175, Lerapolturev, NBTXR3, Gedeptin, RM-1995, Atezolizumab and others are under different phases of head and neck cancer clinical trials.
• In September 2022, NANOBIOTIX announced randomization of the first patient in Asia in NANORAY-312, a global Phase III registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma who are ineligible for platinum-based chemotherapy.
• In August 2022, Genexine announced the dosing of the first patient in Phase II clinical trial using triple combination therapy in patients with recurrent/metastatic HNSCC. The combination therapy consists of two of Genexine’s proprietary drugs, GX-188E (a first-in-class therapeutic DNA vaccine), GX-I7 (a first-in-class long-acting interleukin 7), and Opdivo (nivolumab), a marketed PD-1 immune checkpoint inhibitor.
• In May 2022, Calliditas announced that it had initiated Phase II head and neck cancer therapy trial. The trial will analyze the impact of setanaxib plus pembrolizumab in patients with CAF-density tumors. Calliditas Therapeutics has randomized the first subject in the proof-of-concept Phase II clinical trial of setanaxib (GKT831) in individuals with squamous cell carcinoma of the head and neck (SCCHN).

Request a sample and discover the recent advances in head and neck cancer treatment drugs @ Head and Neck Cancer Treatment Market

Head and Neck Cancer Overview

Head and neck cancer is a collective term for several different types of cancer. Cancers of the head and neck are classified according to where they begin. The mouth (oral cavity), throat (pharynx), voice box (larynx), sinuses and nose cavity, and salivary glands are all included. Squamous cell carcinoma of the head and neck is the most common type of head and neck cancer (HNSCCA). The majority of HNSCCA begins in the layer of flat cells (the epithelium) that lines the upper aerodigestive tract structures such as the mouth, throat, and voice box.

Head and neck cancer symptoms include a lump in the neck or a sore in the mouth or throat that does not heal, a persistent sore throat, difficulty swallowing, and a change or hoarseness in voice; however, these head and neck cancer symptoms can also be caused by other, less severe illnesses.

For head and neck diagnosis, physical examination/blood and urine tests, endoscopy, biopsy, biomarker testing of the tumor, X-ray/barium swallow, panoramic radiograph, ultrasound, magnetic resonance imaging, bone scan, and other tests are used.

Learn more about the emerging head and neck cancer pipeline therapies @ Head and Neck Cancer Drugs and Therapies

Head and Neck Cancer Therapeutics Assessment

Over 100+ prominent companies are actively involved in the development of therapies for Head and Neck cancer. Among these, certain companies have positioned themselves at the forefront by advancing their Head and Neck cancer drug candidates to the most advanced stage, namely Phase III.

For further information on the head and neck cancer pipeline therapeutics, reach out @ Head and Neck Cancer Drugs and Therapeutic Assessment

Scope of the Head and Neck Cancer Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Intravenous, Oral, Parenteral, Subcutaneous
• Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem cell, Vaccine
• Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, NK cell lectin-like receptor subfamily C antagonists, Poly(ADP-ribose) polymerase 1 inhibitors, Poly(ADP-ribose) polymerase 2 inhibitors, Inhibitor of apoptosis protein inhibitors, T lymphocyte stimulants, Aryl hydrocarbon receptor antagonists, DNA topoisomerase I inhibitors; CD40 ligand expression stimulants; Cell death stimulants; Immunologic cytotoxicity, Galectin 3 inhibitors, CD40 antigen stimulants
• Key Head and Neck Cancer Companies: Innate Pharma, GlaxoSmithKline, Debiopharm, Checkpoint Therapeutics, Quadriga BioSciences, Palleon Pharmaceuticals, Klus Pharma, Bicycle Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Memgen, I-Mab Biopharma, Intensity Therapeutics, Wellmaker Bio, SN BioScience, Carisma Therapeutics, Genentech, Pionyr Immunotherapeutics, Palleon Pharmaceuticals, SN BioScience, Bicycle Therapeutics, Inhibrx, Celldex Therapeutics, Carisma Therapeutics Inc, BioAtla, Jacobio Pharmaceuticals, Compugen, GeoVax, CytomX Therapeutics, PNP Therapeutics, Galectin Therapeutics, Cyteir Therapeutics, Merck KGaA, Boehringer Ingelheim, Transgene, iTeos Therapeutics SA,  IntraGel Therapeutics, Incyte Corporation, Cue Biopharma, Rubius Therapeutics, Alkermes, Corregene Biotechnology, NanoCarrier, Kura Oncology, Betta Pharmaceuticals, Arcus Biosciences, Taiho Pharmaceutical, Astex Pharmaceuticals, Bayer HealthCare, Roche, Vaccinex, Pfizer, BioNTech,  Purple Biotech, Novartis Oncology, Macrogenics, Aveta Biomics, Cellectar Biosciences, Nanobiotix, Nektar Therapeutics, Istari Oncology, Nanobiotix, Aspyrian Therapeutics and others.
• Key Head and Neck Cancer Pipeline Therapies: Niraparib, Xevinapant, , CK-301, QBS10072S, A166, E-602, BT5528, RAPA-201, Mitoxantrone Hydrochloride, MEM-288, TJ004309, SNB-101, INT230-6, CT-0508, WM-S1-030, CDX-1140, PY159, MCLA-129, INBRX-106, Autogene cevumeran, JAB-3068, CAB-ROR2-ADC, CX-2029, Ad/PNP, COM701, Eftilagimod alpha, CYT-0851, GR-MD-02, TG4050, BI 765063, TumoCure, EOS-448, Epacadostat, RTX-321, CUE-101, ALKS 4230, CRTE7A2-01, NC-6004, Tipifarnib, MCLA-129, Zimberelimab, HLX10 Plus HLX07, Tolinapant, BAY1905254, OSI-774, VX15/2503, Palbociclib, Olaparib, NT219, BNT113, Buparlisib, Retifanlimab, Avelumab, APG-157, CLR 131, NBTXR3, Evorpacept, Dostarlimab, NKTR-214, IK-175, Lerapolturev, NBTXR3, Gedeptin, RM-1995, Atezolizuma, and others.

Dive deep into rich insights for new drugs for head and neck cancer treatment, visit @ Head and Neck Cancer Clinical Trials and FDA Approvals

Table of Contents

1. Report Introduction
2. Executive Summary
3. Head and Neck Cancer Current Treatment Patterns
4. Head and Neck Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Head and Neck Cancer Late-Stage Products (Phase-III)
7. Head and Neck Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Head and Neck Cancer Discontinued Products
13. Head and Neck Cancer Product Profiles
14. Head and Neck Cancer Companies
15. Head and Neck Cancer Drugs
16. Dormant and Discontinued Products
17. Head and Neck Cancer Unmet Needs
18. Head and Neck Cancer Future Perspectives
19. Head and Neck Cancer Analyst Review
20. Appendix
21. Report Methodology

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services